The mixed CELIA results may cause near-term volatility. Watch for regulatory feedback and details on the registrational trial design. Tau-directed therapy is a new mechanism; initial market reaction could be positive on cognitive signals, but primary endpoint miss tempers enthusiasm.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $191.26entry
- T+1 · 6mo ago +0.55%α +1.78% · $192.32
- T+5 · 6mo ago −0.93%α −0.22% · $189.47
- T+20 · 5mo ago +4.60%α +5.46% · $200.05
- T+60 · 3mo ago +8.15%α +4.83% · $206.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study missed its primary endpoint (dose response on CDR-SB) but showed slowing of cognitive decline in pre-specified analyses and robust tau reduction across doses. Biogen plans to advance to registrational development, creating a mixed outlook for the stock.
Key Facts
- Phase 2 CELIA study (n=416) of diranersen (BIIB080) in early Alzheimer's disease did not meet its primary endpoint of dose response on CDR-SB at Week 76.
- Pre-specified analyses showed slowing of clinical decline, particularly at the lowest dose (60 mg every 24 weeks).
- Robust reductions in CSF tau and tau PET across all doses, consistent with Phase 1b data.
- Safety profile generally consistent with prior studies; higher serious adverse events at highest dose.
- Biogen plans to engage regulators and initiate registrational development.
- FDA granted Fast Track designation in 2025.
Financial Impact
No financial data in release. Potential market for tau-targeting Alzheimer's therapy is large, but clinical and regulatory path remains uncertain.
Risk Factors
- Primary endpoint miss may raise regulatory hurdles and require larger confirmatory trial.
- Higher serious adverse events at highest dose could limit dosing or risk-benefit profile.
- Competition from amyloid-targeting therapies and other tau-directed programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294711 |
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers